Barclays
SLDB icon

Barclays’s Solid Biosciences SLDB Stock Holding History

Barclays’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-667
Closed -$45K – 6429
2019
Q4 		$45K Sell
667
-7,760
-92% -$856K ﹤0.01% 5765
2019
Q3 		$1.31M Sell
8,427
-5,666
-40% -$641K ﹤0.01% 3390
2019
Q2 		$1.22M Buy
+14,093
New +$1.54M ﹤0.01% 3482

Other funds holding SLDB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return
Monashee Investment Management
Monashee Investment Management Boston, Massachusetts $33.4M AUM 92.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays's SLDB Position: Q3 2026 in Review

Barclays increased its Solid Biosciences (SLDB) stake by 11% in Q3 2026, buying an estimated $66.5K and bringing the position to 72,356 shares worth $523K. The position accounts for ﹤0.01% of the portfolio, ranked #3442.

Barclays first reported a position in SLDB in Q1 2018 and has held it in 35 quarters since. The position peaked at $3.94M in Q1 2019. 57 funds tracked by Wall St. Rank hold SLDB as of Q3 2026.

  • Barclays held 72,356 shares of Solid Biosciences worth $523K as of Q3 2026.
  • Barclays bought 7,353 Solid Biosciences shares in Q3 2026, an estimated $66.5K.
  • Solid Biosciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3442 holding.
  • Barclays first reported a position in Solid Biosciences in Q1 2018 and has held it in 35 quarters since.
  • Barclays's Solid Biosciences position peaked at $3.94M in Q1 2019.
  • 57 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.